CNS Pharmaceuticals, Inc. (CNSP) Stock Score, Valuation & Financial Research
CNS Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.
Quick answer for CNSP
CNS Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 5.30. These figures are a research snapshot, not a buy or sell recommendation.
What CNS Pharmaceuticals, Inc. does
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Company business and revenue
Research reporting period: 2025-12-31. A research update is not a new financial filing.
How the company makes money
CNS Pharmaceuticals is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and other financing activities to fund the research and development of its investigational drug candidates for neurology and oncology.
Products and services
- The company is focused on the development of anti-cancer drug candidates, specifically investigational compounds TPI 287 and Berubicin, designed to penetrate the blood-brain barrier.
Customer types
Clinical trial patients.
Suppliers, materials and equipment
- Contract Research Organizations (CROs) — The company utilizes third-party contract research organizations to conduct clinical trials and manage development activities; specific supplier names are unnamed. Source
Business strengths to evaluate
- Focus on high-need therapeutic areas in neurology and oncology Source
Business risks and research considerations
- History of operating losses and dependence on additional financing Source
- Uncertainty of clinical trial success and regulatory approval Source
Sources: Company research source
Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.
CNSP financial snapshot
Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.
- Wall Street Score:
- Not currently available
- Stored price:
- USD 5.30
- Market capitalization:
- 7.75M (currency not supplied)
- Revenue:
- USD 0.00
- Net income:
- USD -16.7M
- Free cash flow:
- USD -13.83M
- Cash:
- USD 19.99M
- Total debt:
- USD 328.57K
- EPS:
- USD -23.59
What stands out
- Free cash flow is USD -13.83M, negative for the stored period.
- The balance sheet shows USD 19.99M of cash versus USD 328.57K of total debt, an excess of cash over debt on these two reported measures.
- The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.
Company-specific financial comparisons
The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.
- Cash exceeds debt by USD 19.66M using the stored balance-sheet values. This does not include other obligations or restricted cash.
Questions worth answering for CNSP
Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.
- How long can CNSP fund negative free cash flow using its current cash position before it may need more debt or new shares?
- How is CNSP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- What specifically needs to improve for CNSP to reach sustainable profitability?
- What does the current fundamental change risk warning mean for the reliability or interpretation of CNSP's score?
What the numbers mean
A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.
A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-10-01.
Research-input completeness: 73% of the scoring inputs required for this public page are currently available.
How to research CNSP
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.